文献速递前列腺癌

68Ga-PSMA PET对前列腺癌患者管理影响的系统综述与荟萃分析

Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol · 2018-04-18

汇总管理变化比例为54%(95%CI 47-60%),PET阳性率为异质性显著因素(p=0.0486)。在生化失败患者中,放疗、手术、局灶治疗和多模式治疗比例增加,而全身治疗和无治疗比例下降。

要点

  • 68Ga-PSMA PET导致约半数前列腺癌患者的管理方案发生改变。
  • PET阳性率越高,管理变化比例越高(p=0.0486)。
  • 生化失败患者中放疗、手术、局灶和多模式治疗比例增加,全身治疗和无治疗比例下降。

核心结论

  • 68Ga-PSMA PET对前列腺癌患者的管理有较大影响,约54%的患者管理发生改变。
  • PET阳性率是管理变化比例异质性的显著因素(p=0.0486)。

研究设计与样本

  • 系统综述与荟萃分析,检索Pubmed和EMBASE数据库至2018年1月20日。
  • 使用GRADE系统评价研究质量,采用随机效应模型汇总管理变化比例,并进行亚组分析和荟萃回归分析。

主要发现

  • 汇总管理变化比例为54%(95%CI 47-60%)。
  • 荟萃回归分析显示PET阳性率(%)是异质性的显著因素(p=0.0486)。
  • 在生化失败患者中,放疗比例从56%增至61%,手术从1%增至7%,局灶治疗从1%增至2%,多模式治疗从2%增至6%。
  • 在生化失败患者中,全身治疗比例从26%降至12%,无治疗比例从14%降至11%。

临床怎么用

  • 68Ga-PSMA PET可改变约半数前列腺癌患者的管理决策,尤其在高PET阳性率时。
  • 对于生化失败患者,68Ga-PSMA PET后更多患者接受放疗、手术、局灶或多模式治疗,较少接受全身治疗或无治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: 68Gallium prostate-specific membrane antigen positron emission tomography (68Ga-PSMA PET) is an emerging imaging modality for assessment of prostate cancer. Recent studies show promising results regarding its ability to detect recurrent or metastatic prostate cancer superior to that of conventional imaging modalities. However, the impact of 68Ga-PSMA PET on management of patients with prostate cancer has not been well established. OBJECTIVE: To perform a systematic review and meta-analysis to evaluate the impact of 68Ga-PSMA PET on management of patients with prostate cancer. EVIDENCE ACQUISITION: Pubmed and EMBASE databases were searched up to January 20, 2018. We included studies that reported proportion of management change after 68Ga-PSMA PET in patients with prostate cancer. The quality of the studies was evaluated using the GRADE system. The proportion of management changes were pooled using random-effects model. Subgroup analyses and meta-regression analyses were performed to explore heterogeneity. EVIDENCE SYNTHESIS: Fifteen studies (1163 patients) were included. The pooled proportion of management changes was 54% (95% confidence interval 47-60%). At meta-regression analyses, PET positivity (%) was a significant factor of heterogeneity (p=0.0486). For patients with biochemical failure, the proportion of radiotherapy (from 56% to 61%), surgery (from 1% to 7%), focal therapy (from 1% to 2%), and multimodal treatment (from 2% to 6%) increased, whereas that of systemic treatment (from 26% to 12%) and no treatment (from 14% to 11%) decreased with 68Ga-PSMA PET. CONCLUSIONS: 68Ga-PSMA PET had a large impact on the management of patients with prostate cancer. Greater PET positivity was associated with higher proportion of management changes. PATIENT SUMMARY: We reviewed all previous studies assessing the impact of 68Gallium prostate-specific membrane antigen positron emission tomography (68Ga-PSMA PET) in patients with prostate cancer. We found that 68Ga-PSMA PET altered the management in approximately half of the patients.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Han S, Woo S, Kim YJ, et al. Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2018. PMID: 29678358. doi:10.1016/j.eururo.2018.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。